• 1
    Kondo M, Wagers AJ, Manz MG et al. Biology of hematopoietic stem cells and progenitors: Implications for clinical application. Annu Rev Immunol 2003; 21:759806.
  • 2
    Wright DE, Wagers AJ, Gulati AP et al. Physiological migration of hematopoietic stem and progenitor cells. Science 2001; 294:19331936.
  • 3
    Abkowitz JL, Robinson AE, Kale S et al. Mobilization of hematopoietic stem cells during homeostasis and after cytokine exposure. Blood 2003; 102:12491253.
  • 4
    Roberts AW, DeLuca E, Begley CG et al. Broad inter-individual variations in circulating progenitor cell numbers induced by granulocyte colony-stimulating factor therapy. Stem Cells 1995; 13:512516.
  • 5
    Kollet O, Petit I, Kahn J et al. Human CD34(+)CXCR4(-) sorted cells harbor intracellular CXCR4, which can be functionally expressed and provide NOD/SCID repopulation. Blood 2002; 100:27782786.
  • 6
    Lapidot T, Kollet O. The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immune-deficient NOD/SCID and NOD/SCID/B2m(null) mice. Leukemia 2002; 16:19922003.
  • 7
    Levesque JP, Hendy J, Takamatsu Y et al. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest 2003; 111:187196.
  • 8
    Kim CH, Broxmeyer HE. In vitro behavior of hematopoietic progenitor cells under the influence of chemoattractants: Stromal cell-derived factor-1, steel factor, and the bone marrow environment. Blood 1998; 91:100110.
  • 9
    Broxmeyer HE, Orschell CM, Clapp DW et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 2005; 201:13071318.
  • 10
    Princen K, Schols D. HIV chemokine receptor inhibitors as novel anti-HIV drugs. Cytokine Growth Factor Rev 2005; 16:659677.
  • 11
    Tamamura H, Fujii N. The therapeutic potential of CXCR4 antagonists in the treatment of HIV infection, cancer metastasis and rheumatoid arthritis. Expert Opin Ther Targets 2005; 9:12671282.
  • 12
    Juarez J, Bradstock KF, Gottlieb DJ et al. Effects of inhibitors of the chemokine receptor CXCR4 on acute lymphoblastic leukemia cells in vitro. Leukemia 2003; 17:12941300.
  • 13
    Leenen PJ, de Bruijn MF, Voerman JS et al. Markers of mouse macrophage development detected by monoclonal antibodies. J Immunol Methods 1994; 174:519.
  • 14
    Flomenberg N, Devine SM, Dipersio JF et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005; 106:18671874.
  • 15
    Flomenberg N, DiPersio J, Calandra G. Role of CXCR4 chemokine receptor blockade using AMD3100 for mobilization of autologous hematopoietic progenitor cells. Acta Haematol 2005; 114:198205.
  • 16
    Liles WC, Broxmeyer HE, Rodger E et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003; 102:27282730.
  • 17
    Hartmann O, Le Corroller AG, Blaise D et al. Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: Hematologic recovery and costs. A randomized, controlled trial. Ann Intern Med 1997; 126:600607.
  • 18
    Schmitz N, Linch DC, Dreger P et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996; 347:353357.
  • 19
    Beyer J, Schwella N, Zingsem J et al. Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: A randomized comparison. J Clin Oncol 1995; 13:13281335.
  • 20
    Zarco MA, Ribera JM, Urbano-Ispizua A et al. Phenotypic changes in neutrophil granulocytes of healthy donors after G-CSF administration. Haematologica 1999; 84:874878.
  • 21
    Dale DC. Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs 2002; 62 (suppl 1):115.
  • 22
    Bedell C. Pegfilgrastim for chemotherapy-induced neutropenia. Clin J Oncol Nurs 2003; 7:5556 63–64.
  • 23
    Glaspy JA, Shpall EJ, LeMaistre CF et al. Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients. Blood 1997; 90:29392951.
  • 24
    Huhn RD, Yurkow EJ, Tushinski R et al. Recombinant human interleukin-3 (rhIL-3) enhances the mobilization of peripheral blood progenitor cells by recombinant human granulocyte colony-stimulating factor (rhG-CSF) in normal volunteers. Exp Hematol 1996; 24:839847.
  • 25
    Molineux G, McCrea C, Yan XQ et al. Flt-3 ligand synergizes with granulocyte colony-stimulating factor to increase neutrophil numbers and to mobilize peripheral blood stem cells with long-term repopulating potential. Blood 1997; 89:39984004.
  • 26
    Petit I, Szyper-Kravitz M, Nagler A et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 2002; 3:687694.
  • 27
    Hendrix CW, Collier AC, Lederman MM et al. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr 2004; 37:12531262.
  • 28
    Burroughs L, Mielcarek M, Little MT et al. Durable engraftment of AMD3100-mobilized autologous and allogeneic peripheral-blood mononuclear cells in a canine transplantation model. Blood 2005; 106:40024008.
  • 29
    Larochelle A, Krouse A, Metzger M et al. AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. Blood 2006; 107:37723778.
  • 30
    Devine SM, Flomenberg N, Vesole DH et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol 2004; 22:10951102.
  • 31
    Grignani G, Perissinotto E, Cavalloni G et al. Clinical use of AMD3100 to mobilize CD34+ cells in patients affected by non-Hodgkin's lymphoma or multiple myeloma. J Clin Oncol 2005; 23:38713872 comment 3872–3873.
  • 32
    Tamamura H, Fujii N. Two orthogonal approaches to overcome multi-drug resistant HIV-1s: Development of protease inhibitors and entry inhibitors based on CXCR4 antagonists. Curr Drug Targets Infect Disord 2004; 4:103110.
  • 33
    Fujii N, Tamamura H. Peptide-lead CXCR4 antagonists with high anti-HIV activity. Curr Opin Investig Drugs 2001; 2:11981202.
  • 34
    Trent JO, Wang ZX, Murray JL et al. Lipid bilayer simulations of CXCR4 with inverse agonists and weak partial agonists. J Biol Chem 2003; 278:4713647144.
  • 35
    Zhang WB, Navenot JM, Haribabu B et al. A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40-4C are weak partial agonists. J Biol Chem 2002; 277:2451524521.
  • 36
    Maghazachi AA. G protein-coupled receptors in natural killer cells. J Leukoc Biol 2003; 74:1624.
  • 37
    Kowalska MA, Ratajczak J, Hoxie J et al. Megakaryocyte precursors, megakaryocytes and platelets express the HIV co-receptor CXCR4 on their surface: Determination of response to stromal-derived factor-1 by megakaryocytes and platelets. Br J Haematol 1999; 104:220229.